Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its Q1 2022 financial results on May 5, 2022, after market close. A live conference call will follow at 4:30 p.m. EDT to discuss the results and provide a corporate update. Atara is a leader in T-cell immunotherapy, utilizing its unique allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for cancer and autoimmune diseases. The company is advancing its pipeline, notably with tab-cel®, in Phase 3 clinical development for EBV+ PTLD.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a leader in T-cell immunotherapy, announced the grant of inducement awards to Brian Robinson, its new Senior Vice President of Global Medical Affairs. The awards include 73,449 restricted stock units and stock options to purchase 138,067 shares, with a performance-based component for an additional 15,689 shares. These awards are part of Atara’s 2018 Inducement Plan, effective April 18, 2022. All stock options have an exercise price of $7.73 per share, reflecting the closing price on the grant date.
Atara Biotherapeutics has granted 37,538 restricted stock units to five newly hired employees as part of its 2018 Inducement Plan, approved by the Compensation Committee of its Board of Directors. The awards, announced on April 1, 2022, vest over four years, incentivizing employee retention. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to employee engagement as it advances its T-cell immunotherapy platform to develop therapies for cancer and autoimmune diseases.
Atara Biotherapeutics (NASDAQ: ATRA) announces the appointment of Charlene Banard as Chief Technical Officer. Banard will oversee process science, quality, and manufacturing. CEO Pascal Touchon highlighted her extensive experience in advanced therapies, including CAR T. Previously, Banard served at Novartis and Shire, where she managed global quality and advanced product pipelines. Atara is known for its innovative T-cell immunotherapies targeting serious diseases, with its lead program in Phase 3 clinical development for EBV-driven conditions.
Atara Biotherapeutics has announced the acquisition of its cell therapy manufacturing facility in Thousand Oaks, California, by FUJIFILM Diosynth Biotechnologies for USD 100 million. This strategic move, coupled with a long-term supply agreement, aims to enhance Atara's capacity for clinical and commercial-stage allogeneic cell therapies, including promising candidates like tabelecleucel and ATA188 for multiple sclerosis. The agreement is expected to reduce Atara's operating expenses and provide financial support into Q4 2023, aiding in the development of innovative therapies.
Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.
Atara Biotherapeutics (NASDAQ: ATRA) will host an EBV and MS Day on March 22, 2022, from 4:00 p.m. EDT. CEO Dr. Pascal Touchon and the management team will discuss the role of Epstein-Barr virus (EBV) in multiple sclerosis (MS), the development of ATA188, and review Phase 1 clinical data. Renowned experts like Mark Freedman and Lawrence Steinman will provide insights. The event includes a conference call for analysts and investors, with a live webcast available on atarabio.com.
Atara Biotherapeutics (NASDAQ: ATRA) reported granting 45,040 restricted stock units and 39,978 stock options to newly hired employees. These awards were approved by Atara’s Compensation Committee and are part of the 2018 Inducement Plan. The restricted stock units will vest over four years, with 25% vesting on the first anniversary. The stock options have a ten-year term and an exercise price of $10.21 per share. This announcement aligns with Nasdaq Listing Rule 5635(c)(4) requirements.
Atara Biotherapeutics (NASDAQ: ATRA) will have its CEO, Pascal Touchon, participate in a cell therapy panel at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 9:10 a.m. EST. The event emphasizes Atara's leadership in T-cell immunotherapy, particularly leveraging its allogeneic Epstein-Barr virus (EBV) platform for cancer and autoimmune disease treatments. A live webcast will be available on their website, with an archived replay accessible for 30 days post-presentation.
Atara Biotherapeutics (Nasdaq: ATRA) announced that a U.S. BLA submission for tab-cel is not expected in Q2 2022 due to further FDA alignment needed. However, the EU approval is on track for Q4 2022. The company reported a Q4 2021 net loss of $93.3 million and a total operating expense increase of 18% compared to the previous year. Significant advances were made in the development of ATA188 for progressive multiple sclerosis, which has received Fast Track designation from the FDA. Atara also entered a $100 million strategic manufacturing partnership with Fujifilm.
FAQ
What is the current stock price of Atara Biotherapeutics (ATRA)?
What is the market cap of Atara Biotherapeutics (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
